Circulating Tumor Cell Heterogeneity in Neuroendocrine Prostate Cancer by Single Cell Copy Number Analysis

Overview

Journal NPJ Precis Oncol

Publisher Springer Nature

Specialty Oncology

Date 2021 Aug 13

PMID 34385567

Citations 18

Authors

Vincenza Conteduca

Sheng-Yu Ku

Luisa Fernandez

Angel Dago-Rodriquez

Jerry Lee

Adam Jendrisak

Megan Slade

Cole Gilbertson

Jyothi Manohar

Michael Sigouros

Yipeng Wang

Ryan Dittamore

Rick Wenstrup

Juan Miguel Mosquera

Joseph D Schonhoft

Himisha Beltran

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer.

Citing Articles

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2.

Bryce A, Crawford E, Agarwal N, Hussain M, Beltran H, Cooperberg M JU Open Plus. 2024; 2(4).

PMID: 38774467 PMC: 11107999. DOI: 10.1097/ju9.0000000000000138.

ID2 Promotes Lineage Transition of Prostate Cancer through FGFR and JAK-STAT Signaling.

Zhang J, Chen Z, Mao Y, He Y, Wu X, Wu J Cancers (Basel). 2024; 16(2).

PMID: 38254880 PMC: 10814654. DOI: 10.3390/cancers16020392.

G-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer.

Hongo H, Kosaka T, Takayama K, Baba Y, Yasumizu Y, Ueda K PNAS Nexus. 2024; 3(1):pgae002.

PMID: 38250514 PMC: 10799637. DOI: 10.1093/pnasnexus/pgae002.

From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine.

Ren S, Li J, Dorado J, Sierra A, Gonzalez-Diaz H, Duardo A Health Inf Sci Syst. 2023; 12(1):6.

PMID: 38125666 PMC: 10728428. DOI: 10.1007/s13755-023-00264-5.

Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis.

Chaudagar K, Hieromnimon H, Kelley A, Labadie B, Shafran J, Rameshbabu S Clin Cancer Res. 2023; 29(23):4930-4940.

PMID: 37721526 PMC: 10841690. DOI: 10.1158/1078-0432.CCR-23-1441.

References

Epstein J, Amin M, Beltran H, Lotan T, Mosquera J, Reuter V . Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014; 38(6):756-67. PMC: 4112087. DOI: 10.1097/PAS.0000000000000208. View

Greene S, Dago A, Leitz L, Wang Y, Lee J, Werner S . Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis. PLoS One. 2016; 11(11):e0165089. PMC: 5112954. DOI: 10.1371/journal.pone.0165089. View

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I . Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019; 116(23):11428-11436. PMC: 6561293. DOI: 10.1073/pnas.1902651116. View

Scher H, Lu D, Schreiber N, Louw J, Graf R, Vargas H . Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncol. 2016; 2(11):1441-1449. PMC: 5206761. DOI: 10.1001/jamaoncol.2016.1828. View

Malihi P, Graf R, Rodriguez A, Ramesh N, Lee J, Sutton R . Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Clin Cancer Res. 2020; 26(15):4143-4153. PMC: 8043601. DOI: 10.1158/1078-0432.CCR-19-4100. View

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M . Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019; 11(484). PMC: 6525633. DOI: 10.1126/scitranslmed.aav0891. View

Brown L, Halabi S, Schonhoft J, Yang Q, Luo J, Nanus D . Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2021; 27(14):4077-4088. PMC: 8282682. DOI: 10.1158/1078-0432.CCR-20-3471. View

Takashima T, Taniyama D, Sakamoto N, Yasumoto M, Asai R, Hattori T . Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers. Br J Cancer. 2021; 125(1):65-77. PMC: 8257722. DOI: 10.1038/s41416-021-01364-3. View

Conteduca V, Ku S, Puca L, Slade M, Fernandez L, Hess J . SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Mol Cancer Ther. 2020; 19(5):1157-1164. PMC: 7440143. DOI: 10.1158/1535-7163.MCT-19-0926. View

10.

Scher H, Morris M, Stadler W, Higano C, Basch E, Fizazi K . Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34(12):1402-18. PMC: 4872347. DOI: 10.1200/JCO.2015.64.2702. View

11.

Aggarwal R, Huang J, Alumkal J, Zhang L, Feng F, Thomas G . Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018; 36(24):2492-2503. PMC: 6366813. DOI: 10.1200/JCO.2017.77.6880. View

12.

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

13.

Saunders L, Bankovich A, Anderson W, Aujay M, Bheddah S, Black K . A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015; 7(302):302ra136. PMC: 4934375. DOI: 10.1126/scitranslmed.aac9459. View

14.

Conteduca V, Oromendia C, Eng K, Bareja R, Sigouros M, Molina A . Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019; 121:7-18. PMC: 6803064. DOI: 10.1016/j.ejca.2019.08.011. View

15.

Corn P, Heath E, Zurita A, Ramesh N, Xiao L, Sei E . Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019; 20(10):1432-1443. PMC: 6858999. DOI: 10.1016/S1470-2045(19)30408-5. View

16.

Beltran H, Hruszkewycz A, Scher H, Hildesheim J, Isaacs J, Yu E . The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res. 2019; 25(23):6916-6924. PMC: 6891154. DOI: 10.1158/1078-0432.CCR-19-1423. View

17.

Lok B, Gardner E, Schneeberger V, Ni A, Desmeules P, Rekhtman N . PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clin Cancer Res. 2016; 23(2):523-535. PMC: 5241177. DOI: 10.1158/1078-0432.CCR-16-1040. View

18.

Beltran H, Jendrisak A, Landers M, Mosquera J, Kossai M, Louw J . The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2015; 22(6):1510-9. PMC: 4990782. DOI: 10.1158/1078-0432.CCR-15-0137. View

19.

Zhang Q, Han Y, Zhang Y, Liu D, Ming J, Huang B . Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases. Front Oncol. 2021; 10:571308. PMC: 7882702. DOI: 10.3389/fonc.2020.571308. View

20.

Linhoff M, Garg S, Mandel G . A high-resolution imaging approach to investigate chromatin architecture in complex tissues. Cell. 2015; 163(1):246-55. PMC: 4583660. DOI: 10.1016/j.cell.2015.09.002. View